TrialOpen-Label Rollover Study of Levosimendan in PH-HFpEF Patients
Trial details
- Registry ID
- NCT03624010
- Phase
- Phase 2
Drug research
Levosimendan
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Levosimendan 2.5 mg/mL Injectable Solution
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 | TENX | Phase 2 | Completed | 2023-04-25Actual |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603 | TENX | Phase 2 | Completed | 2020-04-07Actual |
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Trial details
- Registry ID
- NCT03541603
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |